Scientific Data (Jul 2024)

Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center

  • Maria Victoria Fernandez,
  • Menghan Liu,
  • Aleksandra Beric,
  • Matt Johnson,
  • Arda Cetin,
  • Maulik Patel,
  • John Budde,
  • Pat Kohlfeld,
  • Kristy Bergmann,
  • Joseph Lowery,
  • Allison Flynn,
  • William Brock,
  • Brenda Sanchez Montejo,
  • Jen Gentsch,
  • Nicholas Sykora,
  • Joanne Norton,
  • Jen Gentsch,
  • Olga Valdez,
  • Priyanka Gorijala,
  • Jessie Sanford,
  • Yichen Sun,
  • Ciyang Wang,
  • Dan Western,
  • Jigyasha Timsina,
  • Tassia Mangetti Goncalves,
  • Anh N. Do,
  • Yun Ju Sung,
  • Guoyan Zhao,
  • John C. Morris,
  • Krista Moulder,
  • David M. Holtzman,
  • Randall J. Bateman,
  • Celeste Karch,
  • Jason Hassenstab,
  • Chengjie Xiong,
  • Suzanne E. Schindler,
  • Joyce (Joy) Balls-Berry,
  • Tammie L. S. Benzinger,
  • Richard J. Perrin,
  • Andrea Denny,
  • B. Joy Snider,
  • Susan L. Stark,
  • Laura Ibanez,
  • Carlos Cruchaga

DOI
https://doi.org/10.1038/s41597-024-03485-9
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 19

Abstract

Read online

Abstract The Knight-Alzheimer Disease Research Center (Knight-ADRC) at Washington University in St. Louis has pioneered and led worldwide seminal studies that have expanded our clinical, social, pathological, and molecular understanding of Alzheimer Disease. Over more than 40 years, research volunteers have been recruited to participate in cognitive, neuropsychologic, imaging, fluid biomarkers, genomic and multi-omic studies. Tissue and longitudinal data collected to foster, facilitate, and support research on dementia and aging. The Genetics and high throughput -omics core (GHTO) have collected of more than 26,000 biological samples from 6,625 Knight-ADRC participants. Samples available include longitudinal DNA, RNA, non-fasted plasma, cerebrospinal fluid pellets, and peripheral blood mononuclear cells. The GHTO has performed deep molecular profiling (genomic, transcriptomic, epigenomic, proteomic, and metabolomic) from large number of brain (n = 2,117), CSF (n = 2,012) and blood/plasma (n = 8,265) samples with the goal of identifying novel risk and protective variants, identify novel molecular biomarkers and causal and druggable targets. Overall, the resources available at GHTO support the increase of our understanding of Alzheimer Disease.